Copyright © 2002 by the European Society of Cardiology.
Amiodarone: pearl or peril?
Division of Cardiology, University of Western Ontario, London, Ontario, Canada
References
- Lumer GB, Roy D, Talajic M. Amiodarone reduces procedures and costs related to atrial fibrillation in a controlled clinical trial. Eur Heart J. 2002;23:10501056
[Abstract/Free Full Text] - Roy D, Talajic M, Dorian P. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913920
[Abstract/Free Full Text] - Catherwood E, Fitzpatrick WD, Greenberg ML. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med. 1999;130:625636
[Abstract/Free Full Text] - Eckman MH, Falk RH, Pauker SG. Cost-effectiveness of therapies for patients with nonvalvular atrial fibrillation. Arch Intern Med. 1998;158:16691677
[Abstract/Free Full Text] - Vorperian KR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a metanalysis. J Am Coll Cardiol. 1997;30:791798[Abstract]
- Sunderji R, Kanji Z, Gin K. Pulmonary effects of low dose amiodarone: A review of the risks and recommendations for surveillance. Can J Cardiol. 2000;16:14351440[ISI][Medline]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||